

Material Issues for Social Value Creation



Contribute to Healthcare

With the aging of society and the COVID-19 pandemic, the need for health maintenance and disease risk reduction/prevention is expanding around the world. In addition, nucleic acid medicine, gene therapy, and regenerative medicine/cell therapy are also attracting attention as new medical technologies due to the advancement of genome analysis and editing technologies. Sumitomo Chemical will continue to contribute to the improvement of people's quality of life by leveraging the technologies it has cultivated in the pharmaceutical business and other areas.

— Basic Policy —

We will work at each stage of prevention, diagnosis, and treatment, including the development and dissemination of materials to combat tropical infectious diseases and the ongoing creation of pharmaceutical products in areas of high unmet medical needs. In particular, in the area of treatment, we will accelerate the research, development, manufacturing, and marketing of products that contribute to people's health by using various modalities, including small molecules and regenerative medicine/cell therapy in the three priority therapeutic areas of psychiatry & neurology and oncology, plus other areas where our proprietary technologies can be utilized.

Treatment

In addition to our own research, we are introducing cutting-edge technologies in every possible way, including technology introductions and joint research with biotech companies and academia. Using these methods, we strive to develop superior therapeutic drugs and technologies, as well as to cultivate new business areas.

Psychiatry & Neurology

Sumitomo Pharma

Main Products

- LATUDA® (atypical antipsychotic)

Compounds under development

- ulotaront (atypical antipsychotic)
- SEP-4199 (treatment for bipolar I depression)
- Allogeneic iPS cell-derived cell therapy (Parkinson's disease, retinal pigment epithelium tear, etc.)

Oncology

Sumitomo Pharma

Nihon Medi-Physics

Main Products

- ORGOVYX® (prostate cancer treatment)

Compounds under development

- Theranostics (therapeutic) → P.79
- TP-3654 (treatment for myelofibrosis)
- DSP-5336 (treatment for acute leukemia)

Others

Sumitomo Chemical

Sumitomo Pharma

Main Products / Businesses

- MYFEMBREE® (treatment for uterine fibroids, endometriosis)
- GEMTESA® (treatment for overactive bladder)
- CMO/CDMO businesses (small molecule drugs, nucleic acid drugs, regenerative medicine/cell therapy products)

Diagnosis

We sell diagnostic radiopharmaceuticals for a wide range of diagnostic purposes, including brain, heart, and malignant tumors, and contribute to appropriate diagnosis by physicians.

Nihon Medi-Physics

Main Products

- Diagnostic radiopharmaceuticals (SPECT diagnostics, PET diagnostics)

Compounds under development

- Theranostics (diagnostics) → P.79

Frontier business

Sumitomo Pharma

Business that provides new solutions to solve social issues in the healthcare field other than pharmaceuticals

Main Products / Products under development

Healthcare solutions using VR and digital devices

Prevention

We are working to prevent infectious diseases from two main perspectives: strengthening immunity through vaccines and promoting the use of infectious disease prevention materials.

Sumitomo Chemical

Sumitomo Pharma

Main Products

- Olyset® Net (malaria prevention)

Compounds under development

- Universal Influenza Vaccine
- Malaria Vaccine